1 Answer

For Immediate Release: Jan. 22, 2010
Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis

The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

14 years ago. Rating: 0
Comment this answer Add new comment